WGS
GeneDx Holdings Corp

4,470
Mkt Cap
$2.36B
Volume
128,478.00
52W High
$170.87
52W Low
$55.17
PE Ratio
-108.76
WGS Fundamentals
Price
$80.39
Prev Close
$80.70
Open
$82.01
50D MA
$112.56
Beta
1.46
Avg. Volume
722,901.85
EPS (Annual)
-$0.7339
P/B
7.66
Rev/Employee
$328,876.15
$3,667.03
Loading...
Loading...
News
all
press releases
GeneDx to Participate in Upcoming Investor Conferences
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor...
Business Wire·3h ago
News Placeholder
More News
News Placeholder
Vestmark Advisory Solutions Inc. Makes New Investment in GeneDx Holdings Corp. $WGS
Vestmark Advisory Solutions Inc. acquired a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with...
MarketBeat·3h ago
News Placeholder
BTIG Research Issues Pessimistic Forecast for GeneDx (NASDAQ:WGS) Stock Price
BTIG Research decreased their price target on GeneDx from $200.00 to $170.00 and set a "buy" rating for the company in a report on Tuesday...
MarketBeat·1d ago
News Placeholder
GeneDx (NASDAQ:WGS) Trading 6.5% Higher on Earnings Beat
GeneDx (NASDAQ:WGS) Stock Price Up 6.5% After Earnings Beat...
MarketBeat·2d ago
News Placeholder
GeneDx Q4 Earnings Call Highlights
GeneDx (NASDAQ:WGS) reported fourth-quarter revenue of $121 million, bringing full-year 2025 revenue to $428 million, as management highlighted accelerating exome and genome testing demand and...
MarketBeat·2d ago
News Placeholder
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Beat Estimates
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +27.27% and +1.50%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
GeneDx (NASDAQ:WGS) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS
GeneDx (NASDAQ:WGS - Get Free Report) issued its earnings results on Monday. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.03...
MarketBeat·2d ago
News Placeholder
GeneDx Slides To Net Loss In Q4; Reaffirms FY26; Shares Up In Pre-market
(RTTNews) - GeneDx Holdings Corp. (WGS), a healthcare company, on Monday reported net loss in the fourth quarter despite higher revenue compared with the previous year...
Nasdaq News: Markets·2d ago
News Placeholder
GeneDx Holdings Q4 Earnings Report: What Investors Need to Know
read more...
Benzinga·2d ago
News Placeholder
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the fourth quarter and full...
Business Wire·2d ago
<
1
2
...
>

Latest WGS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.